Clinical Trial Update: 18F-Flutemetamol and Plaque Vulnerability [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update mentioning 18F-Flutemetamol investigating plaque vulnerability in atherosclerosis across phase 2 and phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• [18F]Flutemetamol (flutemetamol F-18)

Snippet

Sponsor: Maastricht University Medical Center | Conditions: Atherosclerosis | Phase 2, Phase 3 | Status: UNKNOWN